EUCTR2006-007013-20-DK进行中（未招募）1 期
A Phase I/II non-comparative Study of Paclitaxel plus Carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancer
Onkologisk afdeling R and the Unit for Experimental Chemotherapy0 个研究点目标入组 70 人开始时间: 2007年1月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Histological verified epithelial carcinoma derived from ovarian, peritoneum or uterine tubes 2. Women =18 years old. 3. ECOG performance status =2 4. Expected duration of life >3 months. 5. Previous treatment regimen containing platinum and paclitaxel. 6. Platinum and paclitaxel sensitive tumor, defined as a minimum of 6 months from cessation of treatment until disease progression. 7. Measurable or assessable lesion. Patients having increased CA-125 as the only sign on recidive are also eligible. 8. Normal organ functions 9. Signed informed consent before inclusion. 10. Prepared to appear for the planned follow-up visits and capable of handling toxicity.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients treated with an experimental drug within the last 4 weeks before inclusion, and patients who receive other concomitant anticancer treatment. 2. Patients having an active infection, or who have received intravenous antibacterial or antifungal medicine within the last 2 weeks before inclusion. 3. Patients previously treated with an HDAC inhibitor. Patients, who have been treated with Valproate for convulsions can be included, however only if the treatment has taken place > 30 days before inclusion. 4. Patients treated with steroid, who are not stabilized on a firm dose equivalent to a maximum of 10 mg prednisolone per day for the last 4 weeks before inclusion. 5. Previous treatment with more than 1st line chemotherapy. 6. Progression during 1st line treatment regimen containing platin/paclitaxel or disease progression less than 6 months after treatment cessation. 7. Concomitant serious and/or non-controllable medical condition such as noncontrollable infection (including HIV infected patients), hypertension, ischemic heart disease, myocardial infarction within the last 6 months, congestive heart failure. 8. Previous treatment for, or other concomitant malignant disease within the last 5 years, except for curative treated carcinoma in situ cervical cancer or basal cell carcinoma. 9. Previous serious allergic reactions such as anaphylactic shock. 10. Pregnancy or breast feeding (or women within the childbearing age who are not using recognized contraception during the treatment and at least 3 months after treatment cessation). 11. Peripheral neuropathy = grade 2, unless this is due to a medical condition. 13. Patients with history of severe hyper sensitive reactions with regards to products containing Cremophor EL (cyclosporine or K-vitamin) and/or patients with known hypersensitivity towards compounds chemically connected to paclitaxel, carboplatin or vorinostat. 14. Clinical signs of cerebral metastases.
研究者
相似试验
招募中
2 期
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric CancerAdvanced or recurrent gastric cancer previously treated with S-1JPRN-UMIN000008632Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine35
终止
不适用
A phase III clinical study to compare paclitaxel (Genexol®-PM) in combination with standard therapy (gemcitabine/cisplatin) and standard therapy alone (gemcitabine/cisplatin) in patients with advanced biliary tractNeoplasmsKCT0003726Asan Medical Center220
招募中
2 期
Study of Paclitaxel and Carboplatin chemotherapy in metastatic breast carcinomaCTRI/2023/03/051117ALL INDIA INSTITUTE OF MEDICAL SCIENCES Jodhpur
进行中（未招募）
不适用
Breast cancer studyHer-2 negative metastatic or locally advanced inoperable breast cancerMedDRA version: 17.0Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-018025-73-DEGMIHO mbH
进行中（未招募）
1 期
A randomised phase 2 study of paclitaxel with or without GSK1120212 in advanced wt BRAF melanoma - Paclitaxel +/- GSK1120212 in MelanomaEUCTR2011-002545-35-GBniversity of Oxford111